VEDERE BIO LL
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
VEDERE BIO LL
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2019-06-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.vederebio.com
Total Employee:
1+
Status:
Active
Contact:
(857) 201-2700
Email Addresses:
[email protected]
Total Funding:
98 M USD
Technology used in webpage:
Google Google Cloud Apache Traffic Server
Similar Organizations
Cadent Therapeutics
Cadent Therapeutics develops novel medicines that tune and modulate brain rhythms for patients with serious neurological disease.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Eyevance Pharmaceuticals
Eyevance is a provider of ophthalmic products and therapies intended to address unmet medical needs.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Pixieray
Pixieray modernizes traditional eyeglass optics by introducing a pioneering adaptive solution giving anyone perfect vision
Privé Revaux
Privé Revaux Eyewear was built on a shared passion for style and quality with the goal of making it accessible in ways never seen until now.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Triplet Therapeutics
Triplet is developing transformative therapies that treat repeat expansion disorders at their source.
Current Employees Featured
Founder
Investors List
Octagon Capital Advisors
Octagon Capital Advisors investment in Series A - Vedere Bio ll
Retinal Degeneration Fund
Retinal Degeneration Fund investment in Series A - Vedere Bio ll
Casdin Capital
Casdin Capital investment in Series A - Vedere Bio ll
Atlas Venture
Atlas Venture investment in Series A - Vedere Bio ll
Samsara BioCapital
Samsara BioCapital investment in Series A - Vedere Bio ll
Mission BioCapital
Mission BioCapital investment in Series A - Vedere Bio ll
Foundation Fighting Blindness
Foundation Fighting Blindness investment in Series A - Vedere Bio ll
Atlas Venture
Atlas Venture investment in Series A - Vedere Bio ll
Mission BioCapital
Mission BioCapital investment in Series A - Vedere Bio ll
Official Site Inspections
http://www.vederebio.com Semrush global rank: 13.28 M Semrush visits lastest month: 78
- Host name: 172.67.143.43
- IP address: 172.67.143.43
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vedere Bio ll"
Novartis acquires Vedere Bio, adding novel optogenetic gene …
Basel, October 29, 2020 — Novartis announced today that it has acquired Vedere Bio, adding a powerful new platform for AAV-based delivery of gene therapies and a best-in-class …See details»
Vedere Bio ll - Crunchbase Company Profile & Funding
Vedere Bio is developing gene therapy products to restore functional vision to patients who have suffered vision loss. View contacts for Vedere Bio ll to access new leads and connect with …See details»
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene …
Oct 29, 2020 · Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally …See details»
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene …
Oct 29, 2020 · Vedere Bio II, which will be referred to as Vedere going forward, is a privately held, emerging biopharmaceutical company leveraging an ocular gene therapy toolbox to develop a …See details»
Retina International — Novartis Acquires Vedere Bio, a Novel ...
Oct 29, 2020 · Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with photoreceptor …See details»
Vedere Bio II Launches with $77 Million Series A Financing to …
May 18, 2021 · Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision …See details»
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene …
Oct 29, 2020 · Vedere Bio II, which will be referred to as Vedere going forward, is a privately held, emerging biopharmaceutical company leveraging an ocular gene therapy toolbox to develop a …See details»
News - Retinal Degeneration) Fund
Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision loss due …See details»
Vedere Bio II - LinkedIn
Bringing vision back to life. | Vedere Bio II, Inc.® is a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision...See details»
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene …
Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore …See details»
Novartis buys Vedere Bio, whose founders helped blind mice see
Oct 29, 2020 · Cambridge, Massachussetts-based Vedere Bio seeks to introduce light-sensing proteins via a shot into the eye of patients with so-called inherited retinal dystrophies and …See details»
Novartis acquires Vedere Bio - Healio
Oct 29, 2020 · Novartis has acquired Vedere Bio and added a platform for adeno-associated virus-based gene therapy delivery, according to a press release.The acquisition includes two …See details»
Vedere Bio II - PitchBook
Jun 1, 2019 · Developer of ocular gene therapies designed for vision restoration. The company's gene therapy products restore functional vision loss due to photoreceptor cell death by …See details»
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene …
Oct 29, 2020 · Vedere Bio II, which will be referred to as Vedere going forward, is a privately held, emerging biopharmaceutical company leveraging an ocular gene therapy toolbox to develop a …See details»
Vedere Bio II Announces Appointment of Gabor Veres, Ph.D., as …
Jun 22, 2021 · Dr. Veres will provide strategic leadership to Vedere's research organization and will be responsible for driving and expanding the company's pipeline of ocular gene therapies.See details»
Novartis Expands Footprint in Gene and Cell Therapy with
Oct 29, 2020 · Novartis acquired Cambridge, Massachusetts-based Vedere Bio in a deal totaling up to $280 million. The takeout broadens Novartis’ footprint in gene and cell therapy, with …See details»
Vedere Bio II Launches with $77 Million Series A Financing to …
May 18, 2021 · Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision …See details»
Gene therapy start-up Vedere Bio II launches to treat blindness
May 18, 2021 · As its name suggests, Vedere Bio II is a sequel to its predecessor company, Vedere Bio, which Novartis quietly acquired last year in a deal worth up to $280 million. Both …See details»
Vedere Bio II Launches with $77 Million Series A Financing
May 18, 2021 · Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision …See details»
Vedere Bio II Appoints Accomplished Clinician and Researcher …
Apr 26, 2022 · Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging proprietary optogenetics and photoswitch technologies along with novel AAV capsids to …See details»